In a HEK293 transporter panel, dabigatran inhibited ASP+ uptake with IC50 values of 8.1 μM for MATE1, 25.3 μM for MATE2-K and 4.7 μM for OCT2. These cellular off-target measurements should be distinguished from thrombin potency. [2]
Inhibition of thrombin-induced PAR1 cleavage
Cell-based study · HeLa cells expressing N-terminal FLAG-tagged PAR1 [1]
Dabigatran inhibited thrombin-induced PAR1 cleavage. Potency depended on thrombin concentration; at 100 nM dabigatran, cleavage became more evident after 30–60 minutes, whereas inhibition persisted with 300 nM under these conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 1B: 10^-10–10^-6 M dabigatran; Figure 1C: 100 or 300 nM dabigatran
- Exposure duration
- Thrombin preincubated with dabigatran or DMSO for 30 minutes; cell exposure 5 minutes for concentration response, up to 60 minutes for time course
- Method
- Thrombin–dabigatran mixtures applied to cells at 37°C; residual cell-surface N-terminal FLAG detected by ELISA
- Vehicle
- DMSO; final percentage not specified in the inspected assay description
- Co-treatment
- Challenge with 1 or 10 nM thrombin; no-thrombin and thrombin/DMSO controls
- Reported limits
- EC50 error definition and final DMSO percentage not specified; no recommended working concentration inferred.
Methods and source locations
Compound reported in the paper: Dabigatran; Compound label in the paper: dabigatran
Reported research result for dabigatran, not validation of an Adooq batch.
Results first two paragraphs; Figure 1B–C and caption; Methods PAR1 Cleavage, Reagents
Inhibition of PAR1 cleavage induced by 1 nM thrombin after 5 minutes: Cell-surface FLAG ELISA; Figure 1 representative of three independent experiments. Definition of ± for these EC50 values not specified in the inspected text. — Results paragraph 1; Figure 1B inset and caption
Inhibition of PAR1 cleavage induced by 10 nM thrombin after 5 minutes: Cell-surface FLAG ELISA; Figure 1 representative of three independent experiments. Definition of ± for these EC50 values not specified in the inspected text. — Results paragraph 1; Figure 1B inset and caption
Inhibition of organic cation transporter probe uptake
Cell-based study · HEK293-Flp-In cells stably expressing human MATE1, MATE2-K or OCT2 [2]
Dabigatran inhibited ASP+ uptake through all three transporters in a concentration-response validation panel. These are probe-dependent off-target assay results, not thrombin inhibition constants or proof of a clinical drug interaction.
Literature-Reported Treatment Conditions
- Treatment concentration
- Various inhibitor concentrations within the reported general assay range of 0–500 μM; exact dabigatran dilution series not enumerated
- Exposure duration
- ASP+ uptake: 1.5 minutes for MATE transporters; 3 minutes for OCT2
- Method
- Simultaneous exposure to dabigatran and 2 μM ASP+ in HBSS, pH 7.4; cellular fluorescence measured after washing
- Vehicle
- 2% DMSO, held constant in all samples
- Co-treatment
- ASP+ probe; cimetidine used to define nonspecific MATE transport in the assay framework
- Reported limits
- Exact dabigatran concentration series, salt/solvate and compound-specific supplier assignment not stated in the inspected text.
Methods and source locations
Compound reported in the paper: Dabigatran; Compound label in the paper: dabigatran
Reported research result for dabigatran, not validation of an Adooq batch.
Table 3 dabigatran row; Methods Experimental IC50 Determination, Reagents and Cell Culture
MATE1-mediated ASP+ uptake inhibition: Fluorescence uptake assay; ASP+ 2 μM; uptake measured in triplicate at each inhibitor concentration. Parentheses are 95% confidence intervals. — Table 3 dabigatran row and column headings; Experimental IC50 Determination
MATE2-K-mediated ASP+ uptake inhibition: Fluorescence uptake assay; ASP+ 2 μM; uptake measured in triplicate at each inhibitor concentration. Parentheses are 95% confidence intervals. — Table 3 dabigatran row and column headings; Experimental IC50 Determination
OCT2-mediated ASP+ uptake inhibition: Fluorescence uptake assay; ASP+ 2 μM; uptake measured in triplicate at each inhibitor concentration. Parentheses are 95% confidence intervals. — Table 3 dabigatran row and column headings; Experimental IC50 Determination